文献速递术前评估与围术期医学区域麻醉与超声

低剂量右美托咪定对玻璃体视网膜手术后恢复时间的影响:回顾性队列研究

The Influence of Low-Dose Dexmedetomidine on Recovery Times Following Sedation for Vitreoretinal Surgery: A Retrospective Cohort Study.
PubMed 文献 · Anesth Analg · 2025-11-24

该回顾性队列研究纳入玻璃体视网膜手术成人镇静病例,比较使用右美托咪定与未使用者的离院时间。右美托咪定使用比例从2019年<0.7%升至2023年91.3%,6180例右美托咪定病例平均剂量0.24 µg/kg/h,96.3%为间断推注无输注。右美托咪定组平均离院时间与未使用组无显著差异(-2.04分钟;95%CI -5.71至1.65;

要点

  • 低剂量间断推注右美托咪定未延长玻璃体视网膜手术后的离院时间。
  • 右美托咪定使用比例逐年上升,2023年达91.3%。
  • 管理者担心右美托咪定延长离院时间缺乏依据。

核心结论

  • 低剂量间断推注右美托咪定用于玻璃体视网膜手术镇静未显著延长离院时间。

研究设计与样本

  • 回顾性队列研究,数据来自医院电子健康记录系统,纳入2020至2024财年成人玻璃体视网膜手术镇静病例。
  • 使用一般线性模型比较右美托咪定组与非右美托咪定组的离院时间,控制镇静组与年份交互作用及麻醉医生固定效应。

主要发现

  • 右美托咪定使用比例从2019年<0.7%增至2023年91.3%。
  • 6180例右美托咪定病例平均(标准差)剂量为0.24(0.20)µg/kg/h,96.3%为间断推注无输注。

临床怎么用

  • 玻璃体视网膜手术镇静可安全使用低剂量间断推注右美托咪定,无需担心延长离院。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dexmedetomidine for procedural sedation during ophthalmic surgery is popular, in part due to high levels of patient satisfaction and analgesia, and low intraocular pressure and respiratory depression, compared to alternative medications. However, longer recovery times were reported when dexmedetomidine was used for cataract or vitreoretinal surgery. Because of these reports, a concern was raised by our hospital's retinal surgeons and administrators that dexmedetomidine might be delaying discharge home from the postanesthesia care unit. Therefore, we performed a retrospective analysis of discharge times of all patients undergoing vitreoretinal surgery under regional anesthesia and sedation at our high-volume ophthalmology specialty hospital. METHODS: Data from all cases involving vitreoretinal surgery in adults performed with sedation were extracted from the hospital's electronic health record system. Discharge times were calculated from the end of surgery (eye dressings applied) until discharge home from the phase II postanesthesia care unit. Using general linear models, discharge times were compared between patients who received dexmedetomidine or other medications for sedation between fiscal year (July 1 to June 30) 2020 and fiscal year 2024. The modeling controlled for interactions between sedation group and year, and included the anesthesia clinician administering the sedation as a fixed effect. RESULTS: The fraction of cases during which dexmedetomidine was used for sedation during vitreoretinal surgery increased progressively from <0.7% in 2019 to 91.3% by 2023. Among the 6180 cases with dexmedetomidine, the mean (standard deviation ) dose of dexmedetomidine, normalized for body weight and the interval from entering the operating room to the end of surgery, was 0.24 (0.20) µg/kg/h. Intermittent bolus doses were administered without infusion in 96.3% of cases. The mean discharge time among the dexmedetomidine cases did not differ significantly from the 2274 cases without dexmedetomidine (-2.04 minutes; 95% confidence interval, -5.71 to 1.65 minutes; P = .28). CONCLUSIONS: A low-dose, bolus dexmedetomidine technique did not prolong the time to home discharge when administered for sedation during vitreoretinal surgery. Managerial concerns about such use prolonging discharge times following vitreoretinal surgery are unwarranted.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Epstein RH, Dexter F, Gayer S, et al. The Influence of Low-Dose Dexmedetomidine on Recovery Times Following Sedation for Vitreoretinal Surgery: A Retrospective Cohort Study. Anesth Analg. 2025. PMID: 41810884. doi:10.1213/ANE.0000000000007859

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。